Semaglutide plus exercise to reduce fat in the heart and leg muscles.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional trial randomises adults with recent type 2 diabetes to semaglutide plus standard dietary counselling and general activity advice versus semaglutide plus a personalised, supervised programme of resistance and endurance exercise. Imaging scans will measure fat content in the heart and leg muscles before and after the intervention. Eligible participants are 20–75 years old, diagnosed within 10 years, have BMI ≥27 kg/m2, HbA1c ≥7% and are not on insulin, and currently do not meet WHO physical activity recommendations. The programme is delivered at Aberdeen Royal Infirmary and includes supervised exercise sessions and follow-up visits.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with a confirmed diagnosis of type 2 diabetes established in the previous 10 years between the ages of 20 and 75
* HbA1c ≥ 53 mmol/mol (7%) typically on diet and/or metformin/sulphonylureas (and/or sodium-glucose cotransporter-2 inhibitors, Dipeptidyl peptidase 4 inhibitors, thiazolidinediones, but not on insulin)
* Patients who do not meet the WHO recommendations on physical activity (≤150 minutes per week) of moderate-vigorous physical activity (MVPA)
* Patients who have a BMI of ≥27 but with a body weight of less than 140kgs due to limitations of the scanner table weight limit
* Current or recent (within 3 months) eGFR \>30 mL/min/1.73m2)
* Able to understand written and spoken English

Exclusion Criteria:

* Any previously unknown cardiac condition other than mild valvular disease
* Any history of known coronary artery disease (including myocardial infarction and myocardial infarction with normal coronary arteries)
* Any relevant or untreated endocrine condition (i.e. Cushings)
* Impaired renal function (defined as estimated glomerular filtration rate of less than 30 mL/min/1.73m2)
* Blood pressure of more than 180/100 mmHg
* Patients on any other medication known to influence glucose or fatty acids metabolism (niacin, omega-3 fatty acids, other glucagon-like peptide-1 receptor agonists)
* Patients with any dietary habits that may interfere with the investigation (for example high fat vegan diets, as we know form prior research that they have very different intramyocellular fat storage compared to those on no dietary preferences)
* Patients with any history of any medical or surgical condition that in the judgement of the investigators may interfere with the exercise regime (i.e. peripheral vascular disease, arthritis), fatty acids metabolism (i.e. lipid storage diseases) or may compromise the safety of the participant (i.e. neurological syndromes for whom an intense exercise program could result in musculo-skeletal injury or accidents due to loss of balance).
* Patients with a sensitivity to Semaglutide (known hypersensitivity, diabetic retinopathy, pregnancy, history of pancreatitis or history of any cancer)
* Significant asthma or pulmonary disease
* Participants unable to cycle on the ergometer
* Unable to perform exercise testing (e.g. prosthetic limbs)
* Pregnancy, breastfeeding or considering pregnancy.
* Patients who have recently had gastrointestinal contrast or radionuclides
* Inability to lie flat or remain motionless for scanning procedures
* Patients whose girth size cannot allow them to fit in the magnetic resonance scanner (there is no set location to measure as this is different for everyone, but we have a plastic hoop that can be fitted around the largest circumference to check the fit)
* Subjects who are not able to engage into a physical training regime or feel that they do not have the interest or sustained motivation to follow one.
* Participants currently enrolled in other interventional clinical research
* Participants not able to understand written or verbal English

Where it's running

• Cardiac Research Office, Aberdeen Royal Infirmary
  Aberdeen, Aberdeenshire, United Kingdom Recruiting

Study contacts

• Principal investigator: Dana Dawson, DM — University of Aberdeen
• Study coordinator: Alexander Davidson, DM
• Email: alexander.davidson@abdn.ac.uk
• Phone: +441224559573

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Proliverenol for liver fat and insulin resistance in type 2 diabetes

  This study tests whether adding Proliverenol to standard diabetes care can improve liver fat and blood sugar control in adults with type 2 diabetes.

  Recruiting Phase 2 Universitas Sriwijaya · Palembang, South Sumatera · NCT07928661

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Safety test of NNC9836-0001 in adults with overweight/obesity or type 2 diabetes

  This study tests whether the new medicine NNC9836-0001 is safe and tolerable in adults who are overweight or have type 2 diabetes, compared to placebo.

  Recruiting Phase 1 Novo Nordisk A/S · Neuss · NCT07896109

• RIGHTEST iFree 2 CGM in Pregnant Women With Diabetes

  This study tests the accuracy and safety of the RIGHTEST iFree 2 continuous glucose monitor in pregnant adults with type 1, type 2, or gestational diabetes.

  Recruiting Bionime Corporation · Ulm, Baden-Wurttemberg · NCT07889388

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

• Maridebart cafraglutide vs. semaglutide for type 2 diabetes on metformin

  This trial tests whether maridebart cafraglutlide is as good as semaglutide at improving blood sugar in adults with type 2 diabetes who take metformin (with or without an SGLT-2 inhibitor).

  Recruiting at 8 sites Phase 3 Amgen · San Diego, California and 7 other locations · NCT07866066

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.